Rifaximin

Overview

Rifaximin, a gastrointestinal-selective antibiotic , binds the β-subunit of bacterial DNA-dependent RNA polymerase, resulting in inhibition of bacterial RNA synthesis . Rifaximin susceptibility is higher against Gram-positive strains (MIC: 0.03-5 mg/ml) compared to Gram-negative bacteria (MIC: 8-50 mg/mL).

Application

Products | Products > Disease Areas > Bacterial Infection | Products > Disease Areas > Infection | Products > Disease Areas > Cancer | Products > Disease Areas > Viral Infection | Products > Signaling Pathways > Anti-infection | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Research Areas > Infection | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Bacterial | Products > Signaling Pathways > Antibiotic | Products > Signaling Pathways > DNA/RNA Synthesis

Product Information

• Catalog No.: HY-13234
• CAS No.: 80621-81-4
• Molecular Formula: C43H51N3O11
• Molecular Weight: 785.88
• Purity: 99.64%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: ≥ 3 mg/mL (3.82 mM); Clear solution
• Availability: In-stock

Source

Original product source